FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06402331 · clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
110
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Fusion Pharmaceuticals Inc.